$PBIO April 16, 2020 /PRNewswire/ -- Pressure BioS
Post# of 103060
(Total Views: 241)
Posted On: 04/16/2020 12:39:57 PM
$PBIO April 16, 2020 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced that the combination of PBI's patented Pressure Cycling Technology ("PCT" with RedShiftBio's proprietary Microfluidic Modulation Spectroscopy ("MMS" resulted in a powerful new platform for biotherapeutic drug development ("PCT-enhanced MMS" . The Company believes combining both platforms enables the rigorous investigation of protein structure and stability in a streamlined and highly efficient workflow that can be critical in drug development.
The global biopharmaceuticals market was valued at $237 billion in 2018 and is estimated to reach $389 billion in 2024 (https://www.mordorintelligence.com/industry-reports/global-biopharmaceuticals-market-industry). This rapid market growth is attributed to the growing acceptance for biopharmaceuticals based on their ability to treat previously untreatable diseases, resulting in huge market demand. Biopharmaceuticals offer several important benefits, such as highly effective and potent action, fewer side effects, and the potential to cure diseases rather than merely treat the symptoms.
Biopharmaceuticals include vaccines, growth and blood factors, hormones, monoclonal antibodies, and purified proteins. An example of a biopharmaceutical is interferon beta, a protein biologic used alone or in combination with other drugs against a broad spectrum of viral infections, including MERS-CoV (https://www.nature.com/articles/s41467-019-13940-6).
, a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced that the combination of PBI's patented Pressure Cycling Technology ("PCT" with RedShiftBio's proprietary Microfluidic Modulation Spectroscopy ("MMS" resulted in a powerful new platform for biotherapeutic drug development ("PCT-enhanced MMS" . The Company believes combining both platforms enables the rigorous investigation of protein structure and stability in a streamlined and highly efficient workflow that can be critical in drug development. The global biopharmaceuticals market was valued at $237 billion in 2018 and is estimated to reach $389 billion in 2024 (https://www.mordorintelligence.com/industry-reports/global-biopharmaceuticals-market-industry). This rapid market growth is attributed to the growing acceptance for biopharmaceuticals based on their ability to treat previously untreatable diseases, resulting in huge market demand. Biopharmaceuticals offer several important benefits, such as highly effective and potent action, fewer side effects, and the potential to cure diseases rather than merely treat the symptoms.
Biopharmaceuticals include vaccines, growth and blood factors, hormones, monoclonal antibodies, and purified proteins. An example of a biopharmaceutical is interferon beta, a protein biologic used alone or in combination with other drugs against a broad spectrum of viral infections, including MERS-CoV (https://www.nature.com/articles/s41467-019-13940-6).
(0)
(0)Scroll down for more posts ▼